6 Journal of Cardiovascular Medicine 2017, Vol 00 No 00

Acknowledgements

K.K.W. holds an NIHR Clinician Scientist Award; J.G. holds an NIHR-HCS Fellowship Award; M.F.P. holds and NIHR-ICA-CDR Fellowship Award; R.M.C. holds a British Heart Foundation Intermediate Fellowship; M.T.K. is a British Heart Foundation Professor of Cardiology; J.E.L. is funded by a Leeds Charitable Foundation Fellowship; the authors acknowledge the consistent administrative support provided by Mrs Andrea Marchant. This research took place in the National Institute for Health Research Leeds Cardiovascular Clinical Research Facility at Leeds Teaching Hospitals NHS Trust.

K.K.W. researched the topic and devised the study. He and M.D. provided the first draft of the manuscript. M.D. and E.J. collated the database and M.D., under the supervision of D.A.C., undertook primary statistical analysis.

Conflicts of interest

There are no conflicts of interest.

References

1Writing Group; American Heart Association Statistics Committee; Stroke Statistics SubcommitteeMozaffarian D, Benjamin EJ, Go AS. et al. Heart disease and stroke statistics-2016 update: a report from the American Heart Association. Circulation 2016; 133:e38–e360.

2Cazeau S, Leclercq C, Lavergne T, et al. Effects of multisite biventricular pacing in patients with heart failure and intraventricular conduction delay. N Engl J Med 2001; 344:873–880.

3Young JB, Abraham WT, Smith AL, et al. Combined cardiac resynchronization and implantable cardioversion defibrillation in advanced chronic heart failure: the MIRACLE ICD Trial. J Am Med Assoc 2003; 289:2685–2694.

4Abraham WT, Fisher WG, Smith AL, et al. Cardiac resynchronization in chronic heart failure. N Engl J Med 2002; 346:1845–1853.

5Higgins SL, Hummel JD, Niazi IK, et al. Cardiac resynchronization therapy for the treatment of heart failure in patients with intraventricular conduction delay and malignant ventricular tachyarrhythmias. J Am Coll Cardiol 2003; 42:1454–1459.

6Bristow MR, Saxon LA, Boehmer J, et al. Cardiac-resynchronization therapy with or without an implantable defibrillator in advanced chronic heart failure. N Engl J Med 2004; 350:2140–2150.

7Cleland JG, Daubert JC, Erdmann E, et al. The effect of cardiac resynchronization on morbidity and mortality in heart failure. N Engl J Med 2005; 352:1539–1549.

8Cubbon RM, Witte KK. Cardiac resynchronisation therapy for chronic heart failure and conduction delay. BMJ 2009; 338:b1265.

9Moss AJ, Hall WJ, Cannom DS, et al. Cardiac-resynchronization therapy for the prevention of heart-failure events. N Engl J Med 2009; 361:1329–1338.

10Bardy GH, Lee KL, Mark DB, et al. Amiodarone or an implantable cardioverter-defibrillator for congestive heart failure. N Engl J Med 2005; 352:225–237.

11Bryant J, Brodin H, Loveman E, Payne E, Clegg A. The clinical and costeffectiveness of implantable cardioverter defibrillators: a systematic review.

Health Technol Assess 2005; 9:1–150.

12Schuchert A, Muto C, Maounis T, et al., MASCOT study group. Lead complications, device infections, and clinical outcomes in the first year after implantation of cardiac resynchronization therapy-defibrillator and cardiac resynchronization therapy-pacemaker. Europace 2013; 15:71–76.

13Cubbon RM, Gale CP, Kearney LC, et al. Changing characteristics and mode of death associated with chronic heart failure caused by left ventricular systolic dysfunction: a study across therapeutic eras. Circ Heart Fail 2011; 4:396–403.

14National Insistitue of Health and Clinical Excellence. Cardiac resynchronisation therapy for the treatment of heart failure. 2007; NICE technology appraisal guidance 120. Available at: https://www.nice.org.uk/ guidance/ta120. [Accessed 1 June 2017].

15Cleland JG, Daubert JC, Erdmann E, et al. Longer-term effects of cardiac resynchronization therapy on mortality in heart failure [the CArdiac REsynchronization-Heart Failure (CARE-HF) trial extension phase]. Eur Heart J 2006; 27:1928–1932.

16Gold MR, Thebault C, Linde C, et al. Effect of QRS duration and morphology on cardiac resynchronization therapy outcomes in mild heart failure: results from the Resynchronization Reverses Remodeling in Systolic Left Ventricular Dysfunction (REVERSE) study. Circulation 2012; 126:822–829.

17Fruhwald FM, Fahrleitner-Pammer A, Berger R, et al. Early and sustained effects of cardiac resynchronization therapy on N-terminal pro-B-type natriuretic peptide in patients with moderate to severe heart failure and cardiac dyssynchrony. Eur Heart J 2007; 28:1592–1597.

18Barsheshet A, Wang PJ, Moss AJ, et al. Reverse remodeling and the risk of ventricular tachyarrhythmias in the MADIT-CRT (Multicenter Automatic Defibrillator Implantation Trial-Cardiac Resynchronization Therapy). J Am Coll Cardiol 2011; 57:2416–2423.

19Sutton MG, Plappert T, Hilpisch KE, et al. Sustained reverse left ventricular structural remodeling with cardiac resynchronization at one year is a function of etiology: quantitative Doppler echocardiographic evidence from the Multicenter InSync Randomized Clinical Evaluation (MIRACLE). Circulation 2006; 113:266–272.

20Looi KL, Gajendragadkar PR, Khan FZ, et al. Cardiac resynchronisation therapy: pacemaker versus internal cardioverter-defibrillator in patients with impaired left ventricular function. Heart 2014; 100:794–799.

21Cleland JG, Pellicori P, Dicken B. Why does CRT reduce the risk of arrhythmias? JACC Cardiovasc Imaging 2013; 6:445–447.

22Shen L, Jhund PS, Petrie MC, et al. Declining risk of sudden death in heart failure. N Engl J Med 2017; 377:41–51.

23Moss AJ, Zareba W, Hall WJ, et al. Prophylactic implantation of a defibrillator in patients with myocardial infarction and reduced ejection fraction. N Engl J Med 2002; 346:877–883.

24Kober L, Thune JJ, Nielsen JC, et al. Defibrillator implantation in patients with nonischemic systolic heart failure. N Engl J Med 2016; 375:1221–1230.

25Lindenfeld J, Feldman AM, Saxon L, et al. Effects of cardiac resynchronization therapy with or without a defibrillator on survival and hospitalizations in patients with New York Heart Association class IV heart failure. Circulation 2007; 115:204–212.

26Carson P, Anand I, O’Connor C, et al. Mode of death in advanced heart failure: the Comparison of Medical, Pacing, and Defibrillation Therapies in Heart Failure (COMPANION) trial. J Am Coll Cardiol 2005; 46:

2329–2334.

27Kutyifa V, Geller L, Bogyi P, et al. Effect of cardiac resynchronization therapy with implantable cardioverter defibrillator versus cardiac resynchronization therapy with pacemaker on mortality in heart failure patients: results of a high-volume, single-centre experience. Eur J Heart Fail 2014; 16:1323–1330.

28Marijon E, Leclercq C, Narayanan K, et al. Causes-of-death analysis of patients with cardiac resynchronization therapy: an analysis of the CeRtiTuDe cohort study. Eur Heart J 2015; 36:2767–2776.

29Brignole M, Auricchio A, Baron-Esquivias G, et al., ESC Committee for Practice Guidelines (CPG). 2013 ESC Guidelines on cardiac pacing and cardiac resynchronization therapy The Task Force on cardiac pacing and resynchronization therapy of the European Society of Cardiology (ESC). Developed in collaboration with the European Heart Rhythm Association (EHRA). Eur Heart J 2013; 34:2281–2329.

30Epstein AE, DiMarco JP, Ellenbogen KA, et al., American College of Cardiology/American Heart Association Task Force on Practice Guidelines (Writing Committee to Revise the ACC/AHA/NASPE 2002 Guideline Update for Implantation of Cardiac Pacemakers and Antiarrhythmia Devices); American Association for Thoracic Surgery; Society of Thoracic Surgeons. ACC/AHA/HRS 2008 Guidelines for Device-Based Therapy of Cardiac Rhythm Abnormalities A Report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (Writing Committee to Revise the ACC/AHA/NASPE 2002 Guideline Update for Implantation of Cardiac Pacemakers and Antiarrhythmia Devices) Developed in Collaboration With the American Association for Thoracic Surgery and Society of Thoracic Surgeons. Circulation 2008; 117:E350–E408.

31Yao GQ, Freemantle N, Calvert MJ, et al. The long-term cost-effectiveness of cardiac resynchronization therapy with or without an implantable cardioverter-defibrillator. Eur Heart J 2007; 28:42–51.

32Brignole M. Are complications of implantable defibrillators under-estimated and benefits over-estimated? Europace 2009; 11:1129–1133.

33Feldman AM, de Lissovoy G, Bristow MR, et al. Cost effectiveness of cardiac resynchronization therapy in the Comparison of Medical Therapy, Pacing, and Defibrillation in Heart Failure (COMPANION) trial. J Am Coll Cardiol 2005; 46:2311–2321.

34Gold MR, Padhiar A, Mealing S, et al. Economic value and costeffectiveness of cardiac resynchronization therapy among patients with mild heart failure projections from the REVERSE long-term follow-up. JACC Heart Fail 2017; 5:204–212.